Tilray Inc (NASDAQ:TLRY)

43.41
Delayed Data
As of Jul 18
 -0.84 / -1.90%
Today’s Change
20.10
Today|||52-Week Range
300.00
-38.46%
Year-to-Date
Zacks Market Edge Highlights: MJ, YOLO, THCX, TLRY and CRON
Jul 18 / Zacks.com - Paid Partner Content
3 Pot Stocks Short-Sellers Are Targeting
Jul 11 / MotleyFool.com - Paid Partner Content
Where Will Tilray Be in 5 Years?
Jul 18 / MotleyFool.com - Paid Partner Content
The 6 Best Marijuana Stocks in June
Jul 08 / MotleyFool.com - Paid Partner Content
How Beyond Meat's Stock Price Proves the Market Is Rational
Jul 18 / MotleyFool.com - Paid Partner Content
Thinking about buying stock in Aethlon Medical, Alibaba, Canopy Growth, Eros Internat...
Jul 02 / PR NewswirePRN - Paid Partner Content
Should You Buy a Cannabis ETF?
Jul 17 / Zacks.com - Paid Partner Content
Blueberries Announces Appointment of Chief Financial Officer
Jun 24 / GlobeNewswirePNW - Paid Partner Content
U.S. CBD Sales to Grow an Average of 107% Annually Through 2023
Jul 14 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close44.25
Today’s open43.87
Day’s range42.69 - 44.13
Volume1,042,816
Average volume (3 months)1,616,676
Market cap$4.2B
Data as of 4:00pm ET, 07/18/2019

Growth & Valuation

Earnings growth (last year)-873.51%
Earnings growth (this year)-26.73%
Earnings growth (next 5 years)--
Revenue growth (last year)+110.00%
P/E ratioNM
Price/Sales135.76
Price/Book20.43

Competitors

 Today’s
change
Today’s
% change
ONCESpark Therapeutics I...+1.16+1.20%
MRNAModerna Inc+0.23+1.64%
BPMCBlueprint Medicines ...+1.91+1.98%
MORMorphoSys AG+0.54+1.98%
Data as of 4:00pm ET, 07/18/2019

Financials

Next reporting dateAugust 28, 2019
EPS forecast (this quarter)-$0.26
Annual revenue (last year)$43.1M
Annual profit (last year)-$67.7M
Net profit margin-157.02%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Brendan Kennedy
Executive Vice President-
Operations
Greg Christopher
Corporate headquarters
Nanaimo, British Columbia

Forecasts